GLPwatch
Papers (9189)
Page 105 of 154, ranked by citation count.
- G protein-coupled receptors and obesity.
- Psychiatric and psychological adverse effects associated with dulaglutide, semaglutide, and liraglutide: A vigibase study.
- Treatment satisfaction with ITCA 650, a novel drug-device delivering continuous exenatide, versus twice-daily injections of exenatide in type 2 diabetics using metformin.
- Comparison of twelve single-drug regimens for the treatment of type 2 diabetes mellitus.
- Prognostic benefit of glucagon-like peptide-1 receptor agonists addition to sodium-glucose cotransporter 2 inhibitors in patients with atherosclerotic cardiovascular disease and heart failure: a cohort study.
- Double-strand adeno-associated virus-mediated exendin-4 expression in salivary glands is efficient in a diabetic rat model.
- Cardiovascular safety outcomes of new antidiabetic therapies.
- A comprehensive study on the identification and characterization of major degradation products of synthetic liraglutide using liquid chromatography-high resolution mass spectrometry.
- Olfactory dysfunction in type II diabetes: Therapeutic options and lessons learned from other etiologies - A scoping review.
- Combined Treatment With Exenatide and Cyclosporine A or Parstatin 1-26 Results in Enhanced Reduction of Infarct Size in a Rabbit Model.
- Effects of addition of a dipeptidyl peptidase IV inhibitor to metformin on sirolimus-induced diabetes mellitus.
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- Real-world comparison of treatment patterns and effectiveness of albiglutide and liraglutide.
- Hearing protection and damage mitigation in Chinchillas exposed to repeated low-intensity blasts.
- Exendin-4 Exacerbates Burn-Induced Morbidity in Mice by Activation of the Sympathetic Nervous System.
- Dulaglutide as a demethylating agent to improve the outcome of breast cancer.
- A systematic review of the economic value proposition for commercially available nonsurgical weight-loss interventions.
- Prepregnancy GLP-1RA use improves maternal lipid metabolism via liver-secreted FGF21 during pregnancy in HFD-fed dams.
- Beyond fat: Does semaglutide affect lean mass?
- Tirzepatide highly effective for weight loss.
- Effect of once-weekly exenatide on hospitalization for acute coronary syndrome or coronary revascularization in patients with type 2 diabetes mellitus.
- A GLP‑1 receptor agonist attenuates human islet amyloid polypeptide‑induced autophagy and apoptosis in MIN6 cells.
- The Hypoglycemic and Hypocholesterolemic Activity of <i>Dioscorea deltoidea</i>, <i>Tribulus terrestris</i> and <i>Panax japonicus</i> Cell Culture Biomass in Rats with High-Fat Diet-Induced Obesity.
- Long-Acting and Stapled GLP-1R/GIPR/GCGR Triple Agonist for the Treatment of Obesity and Atherosclerosis.
- Association of Baseline Factors With Glycemic Outcomes in GRADE: A Comparative Effectiveness Randomized Clinical Trial.
- The Anti-Inflammatory Effects of Liraglutide in Equine Inflammatory Joint Models.
- Classification of Non-Insulin Glucose Lowering Drugs.
- Assessment of Exenatide Extended-Release for Maintenance of Diabetic Remission in Cats.
- Bypassing Prescribers and Pharmacists: Online Purchasing of Semaglutide and Tirzepatide "For Research Purposes".
- Combination Therapy With Semaglutide and Dapagliflozin as an Effective Approach for the Management of Type A Insulin Resistance Syndrome: A Case Report.
- GLP-1 receptor agonists show no detrimental effect on sperm quality in mouse models and cell lines.
- Pharmacokinetic properties and effects of PT302 after repeated oral glucose loading tests in a dose-escalating study.
- Oral Semaglutide Led to Similar Weight Loss as Injection, Company Says.
- Does Therapy with Glucagon-like Peptide 1 Receptor Agonists Have an Effect on Biochemical Markers of Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD)? Pleiotropic Metabolic Effect of Novel Antidiabetic Drugs in Patients with Diabetes-Interventional Study.
- Liraglutide suppresses ferroptosis by upregulation NRF2 in type 2 diabetic cardiomyopathy.
- [New drug for type 2 diabetes: introduction of oral Semaglutide (Rybelsus<sup>®</sup> tablets), an oral GLP-1 receptor agonist].
- Severe Hypomagnesemia and Hypocalcemia Linked to Semaglutide in Type 2 Diabetes: A Case Report.
- Exenatide extended-release; clinical trials, patient preference, and economic considerations.
- Long-acting PYY<sub>3</sub> <sub>-36</sub> analogue with semaglutide for obesity: from preclinical assessment through randomized clinical studies.
- Liraglutide pharmacotherapy reduces body weight and improves glycaemic control in juvenile obese/hyperglycaemic male and female rats.
- Liraglutide for the Treatment of Obesity: Analyzing Published Reviews.
- Glucagon-like Peptide-1 Receptor Agonists in the Management of Diabetic Retinopathy.
- Study protocol of a randomised controlled trial comparing perioperative intravenous insulin, GIK or GLP-1 treatment in diabetes-PILGRIM trial.
- Is the GLP-1 receptor agonist, semaglutide, a good option for weight loss in persons with HIV?
- The blood pressure-lowering property of subcutaneous semaglutide: a systematic review, meta-analysis, and meta-regression.
- GLP-1 agonists to slow down Parkinson's progression? The quest continues.
- HbA1c Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial.
- How to fight obesity with antidiabetic drugs: targeting gut or kidney?
- REWIND to fast forward: time to revisit stroke prevention in type 2 diabetes?
- Semaglutide Pretreatment Induces Cardiac Autophagy to Reduce Myocardial Injury in Septic Mice.
- GLP-1RAs regulate lipid metabolism and induce autophagy through AMPK/SIRT1 pathway to improve NAFLD.
- A double-blind, placebo-controlled trial of exenatide for the treatment of olanzapine-related weight gain in obese and overweight adults.
- Liraglutide effective in the severely insulin-resistant patient with type 2 diabetes requiring U-500 insulin: a case report.
- Efficacy and Safety of GLP- 1 Receptor Agonists in the Management of Weight Recurrence or Suboptimal Clinical Response after Undergoing Metabolic Bariatric Surgeries: A Meta-Analysis.
- Enhancing bile tolerance of Lactobacilli is involved in the hypolipidemic effects of liraglutide.
- Liraglutide Reduces Liver Steatosis and Improves Metabolic Indices in Obese Patients Without Diabetes: A 3-Month Prospective Study.
- Influence and significance of intervening diabetes microRNA expression profile of NOD mice with exendin-4.
- Safety and efficacy of the combination of the glucagon-like peptide-1 receptor agonist liraglutide with an oral antidiabetic drug in Japanese patients with type 2 diabetes: Post-hoc analysis of a randomized, 52-week, open-label, parallel-group trial.
- Association between glucagon-like peptide-1 agonists and risk of diabetic retinopathy: a disproportionality analysis using FDA adverse event reporting system data.
- Initiating Titratable Fixed-Ratio Combinations of Basal Insulin Analogs and Glucagon-Like Peptide-1 Receptor Agonists: What You Need to Know.